Ghrelin nerve signals from the ARC to the DVC regulate glycolipid metabolism, an effect blocked by GHRP-6
Background
The central nervous system, particularly the hypothalamus, plays a critical role in maintaining metabolic homeostasis. The arcuate nucleus (ARC) and the dorsal vagal complex (DVC) are key brain regions involved in this regulation. Ghrelin, a peptide hormone primarily known for stimulating appetite, also influences glucose and lipid metabolism through its receptor, the growth hormone secretagogue receptor type 1a (GHSR-1a). While the presence and function of ghrelin pathways are known, the specific neural circuits connecting different brain regions and their precise roles in metabolic control remain poorly understood. This study investigates a previously uncharacterized ghrelin-mediated neural pathway from the ARC to the DVC, aiming to clarify its specific function in the regulation of glycolipid metabolism and its potential as a therapeutic target.
Study Design
Researchers used a rat model to investigate the ghrelin pathway. They confirmed GHSR-1a protein and mRNA expression in the DVC using immunohistochemistry and PCR. Neural connections were mapped using retrograde tracing combined with fluorescence immunohistochemical staining. To determine function, the ARC was subjected to electrical stimulation (ES). The effects on DVC neuronal activity were measured electrophysiologically. Systemic effects on glycolipid metabolism and liver enzyme expression were assessed via biochemical analysis, qRT-PCR, and Western blot. A key control arm involved pre-treating the DVC with the ghrelin receptor antagonist [D-Lys-3]-GHRP-6 before ARC stimulation to confirm the pathway's dependence on ghrelin signaling.
Results
The study confirmed that GHSR-1a is expressed on DVC neurons and that ghrelin-producing nerve fibers project directly from the ARC to the DVC. Electrical stimulation of the ARC activated both glucose-excited and glucose-inhibited neurons in the DVC that were responsive to ghrelin. This stimulation produced significant, adverse changes in metabolic markers.
ARC stimulation significantly elevated serum triglyceride, total cholesterol, and LDL-C, while reducing beneficial HDL-C. It also increased serum glucose and decreased serum insulin levels, indicating a disruption of glucose homeostasis.
In the liver, ARC stimulation increased the expression of acetyl-CoA carboxylase-1 (ACC-1) and decreased carnitine palmitoyltransferase-1 (CPT-1), a profile that promotes lipid accumulation. Critically, all of these metabolic effects were partially blocked by administering the ghrelin antagonist [D-Lys-3]-GHRP-6 directly into the DVC and were also reduced by vagotomy (cutting the vagus nerve), confirming the pathway's functional relevance.
Key Findings
- Ghrelin fibers originating in the arcuate nucleus (ARC) project directly into the dorsal vagal complex (DVC).
- Electrical stimulation of the ARC increased serum triglyceride, total cholesterol, LDL-C, and glucose levels.
- Electrical stimulation of the ARC decreased serum high-density lipoprotein (HDL-C) and insulin levels.
- Pre-treatment with the ghrelin receptor antagonist [D-Lys-3]-GHRP-6 in the DVC partially blocked the metabolic effects of ARC stimulation.
- ARC stimulation increased liver ACC-1 and decreased CPT-1 expression, promoting lipid accumulation.
Why It Matters
This research maps a specific neural circuit through which the brain, via ghrelin signaling, directly influences liver function and systemic lipid and glucose levels. For individuals exploring metabolic optimization, it highlights that ghrelin's effects are not just systemic but are mediated by precise brain-to-periphery pathways. The key takeaway is that central ghrelin signaling in the ARC-DVC axis can actively worsen lipid profiles and glucose control. This suggests that centrally-acting ghrelin antagonists, or interventions that modulate vagal nerve output, could be explored for managing metabolic disorders. The use of [D-Lys-3]-GHRP-6 as a tool to block these effects underscores the potential for targeted receptor modulation within specific brain regions to correct metabolic imbalances. This is still preclinical animal research, far from a human protocol, but it provides a mechanistic rationale for investigating vagal and central ghrelin pathways in metabolic disease.
